TMCnet - World's Largest Communications and Technology Community



Research and Markets: Retinal Degeneration - Pipeline Review, H2 2013 Report
[January 28, 2014]

Research and Markets: Retinal Degeneration - Pipeline Review, H2 2013 Report

DUBLIN --(Business Wire)--

Research and Markets ( has announced the addition of the "Retinal Degeneration - Pipeline Review, H2 2013" report to their offering.

'Retinal Degeneration - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Retinal Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Retinal Degeneration.


- A snapshot of the global therapeutic scenario for Retinal Degeneration.

- A review of the Retinal Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Retinal Degeneration pipeline on the basis of route of administration and molecule type.

- Key discontinued pipeline projects.

- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Retinal Degeneration.

- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.

- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.

- Devise corrective measures for pipeline projects by understanding Retinal Degeneration pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned

SanBio, Inc.

to-BBB technologies BV

Aprogen, Inc.

X-BODY BioSciences, Inc.

GenSight Biologics

Bionature E.A. Ltd.

Spark Therapeutics, LLC

For more information visit

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

[ Back To's Homepage ]

Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments:
Comments about this site:


© 2018 Technology Marketing Corporation. All rights reserved | Privacy Policy